Abstract
The era of targeted therapy for glioblastoma has arrived, but results have been modest thus far. This review highlights the challenges inherent to treating glioblastoma with targeted therapy and delves into the complex signaling networks that form the molecular basis of novel therapies. Past failures, current challenges, and future possibilities are discussed in the context of the classic "oncogenic" signaling network, as well as the "nononcogenic" stress response network.